The October 15 short interest data has been compared with the September 30 figures, and the trend in biotech leaders had changed from directional to short sellers becoming stock-specific in their focus. Amgen Inc. (NASDAQ: AMGN) saw its …
Traders faced front and center as continued turmoil in Italy weighed on major stock indexes as details of France’s new …
AMGN Earnings in Focus The company reported earnings of $2.30 ... Gilead's shares dropped 4% in extending market trading on account of the Solvadi sales miss. Though the stock might trade lower for some more days, it nonetheless …
co will make upfront payment of $40 million and purchase $20 million of cytomx common stock.CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for EGFR program.CytomX to be able …
We expect shares to trade off on the elevated expenses though the stock market was arguably prepared for it with ... and 3.8% dividend yield. Amgen (AMGN): Reiterate outperform rating. Remain buyers after a solid fourth quarter beat and …
Amgen Inc. (NASDAQ: AMGN) is one the top blue-chip stocks in the biotech world ... Deutsche Bank has a $195 price objective for the stock. The Thomson/First Call consensus price target is $176.32. The stock closed Tuesday at $154.24.
Amgen Inc. (AMGN) Amgen, which is scheduled to release earnings after ... But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% …
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal – making it the fifth-largest biotech deal in history …
Amgen (NASDAQ: AMGN) PCSK9 gets positive opinion from EMA, according to Bloomberg headlines. UPDATE - More …
Drug stocks are soaring Wednesday, after Democratic presidential candidate Hillary Clinton, who had outlined plans to to curb drug price increases was defeated by Republican Donald Trump. Morgan Stanley analysts summed up the sigh of …